AIM： To investigate the prevalence of cholelithiasis among patients treated with ezetimibe. METHODS： A retrospective, case-control study based on computerized medical records from patients of the Clalit Health Servi...AIM： To investigate the prevalence of cholelithiasis among patients treated with ezetimibe. METHODS： A retrospective, case-control study based on computerized medical records from patients of the Clalit Health Services, Sharon-Shomron region, from 2000 to 2009. Patients 20-85 years of age, who had been treated with ezetimibe and statins or statins only for at least 6 too, and who had an abdominal ultrasound were included in the study. Collected data included age, gender, ezetimibe treatment duration, presence of hypothyroidism or diabetes, and existence of cholelithiasis as determined by ultrasound. Ex- cluded were subjects after gallbladder resection, with hemolysis, myeloproliferative or inflammatory bowel diseases, and those treated with ursodeoxycholic acid and fibrates. Patients treated with statins and ezeti- mibe （study group） were compared to patients treated with statins only （control group）. RESULTS： The study group included 25 patients and the control group 168. All patients in the study were treated with statins. The study group included 13 males （52%） and 12 females （48%）, the control group 76 males （45%） and 92 （55%） females （P = 0.544）. The groups did not differ in age （mean age： 68 ± 8 years, range 53-85 years vs mean age： 71±8 years, range 51-85 years; P = 0.153） or in the rate of dia- betic and hypothyroid patients [11 （44%） vs 57 （33%）, P = 0.347 in the study group and 5 （20%） vs 23 （14%）, P = 0.449 in the control group, respectively]. Patients in the study group were treated with ezetimibe for an average of 798±379 d. Cholelithiasis was found in 4 （16%） patients in the study group and in 33 （20%） patients in the control group （P = 0.666）. CONCLUSION： Ezetimibe does not appear to influ- ence the prevalence of gallstones.展开更多
目的研究姜黄素与高脂饮食小鼠胆囊胆固醇性结石关系及可能参与调控过程的因子。方法将C57BL6小鼠50只随机分为5组,其中一组予普通饲料,其余四组予高脂饮食饲料,同时灌喂不同剂量姜黄素[0、200、500、1 000 mg/(kg·d)],共4周。计...目的研究姜黄素与高脂饮食小鼠胆囊胆固醇性结石关系及可能参与调控过程的因子。方法将C57BL6小鼠50只随机分为5组,其中一组予普通饲料,其余四组予高脂饮食饲料,同时灌喂不同剂量姜黄素[0、200、500、1 000 mg/(kg·d)],共4周。计算小鼠胆囊结石成石率,收集小鼠血液、胆囊胆汁、胆囊、肝脏以及小肠。计算胆囊容积,称量肝脏质量,检测血液及胆汁胆固醇、甘油三酯等生化指标。用Realtime PCR及Western blotting方法分别检测小鼠小肠上皮NPC1L1及SREBP2 m RNA及蛋白表达。结果姜黄素能够降低小鼠胆囊结石的发生,大剂量姜黄素可降低胆囊结石发生率达60%,同时降低肝脏脂肪变性程度,降低小鼠血液胆固醇饱和度。同时,姜黄素可以抑制高脂饮食所致的NPC1L1 m RNA表达上调[(2.65±0.04)vs(2.06±0.07),(1.69±0.06),(1.33±0.05),P<0.01],且呈现剂量依赖关系,降低高脂饮食所致的NPC1L1蛋白高表达。姜黄素还可以抑制高脂饮食所致的SREBP2 m RNA表达上调[(1.34±0.08)vs(1.39±0.03),(1.19±0.01),(1.06±0.03),P<0.05],且呈现剂量依赖关系,降低高脂饮食所致的SREBP2蛋白表达上调。结论姜黄素能够降低高脂饮食小鼠胆囊结石的形成,NPC1L1和SREBP2可能参与了这个过程。展开更多
目的:研究尼曼匹克C1样1(Niemann Pick C1 like 1,NPC1L1)基因启动子-762T>C多态性的活性差异及药物对其的调节作用。方法:分别构建含NPC1L1基因-762T>C多态性的T/C等位基因启动子荧光酶报告基因,测定启动子活性以及不同药物处理...目的:研究尼曼匹克C1样1(Niemann Pick C1 like 1,NPC1L1)基因启动子-762T>C多态性的活性差异及药物对其的调节作用。方法:分别构建含NPC1L1基因-762T>C多态性的T/C等位基因启动子荧光酶报告基因,测定启动子活性以及不同药物处理后启动子活性的改变。结果:含T或C等位基因的NPC1L1基因启动子活性无统计学差异(P>0.05)。外源性胆固醇和依泽麦布均在高浓度抑制两种启动子活性,辛伐他汀则增强两种启动子活性(P<0.05),但两种基因型启动子之间对药物依泽麦布和辛伐他汀的反应无统计学差异(P>0.05)。结论:胆固醇和依泽麦布能抑制NPC1L1转录活性活性,辛伐他汀则增强NPC1L1转录活性,而-762T>C多态性不影响启动子活性及药物反应。展开更多
文摘AIM： To investigate the prevalence of cholelithiasis among patients treated with ezetimibe. METHODS： A retrospective, case-control study based on computerized medical records from patients of the Clalit Health Services, Sharon-Shomron region, from 2000 to 2009. Patients 20-85 years of age, who had been treated with ezetimibe and statins or statins only for at least 6 too, and who had an abdominal ultrasound were included in the study. Collected data included age, gender, ezetimibe treatment duration, presence of hypothyroidism or diabetes, and existence of cholelithiasis as determined by ultrasound. Ex- cluded were subjects after gallbladder resection, with hemolysis, myeloproliferative or inflammatory bowel diseases, and those treated with ursodeoxycholic acid and fibrates. Patients treated with statins and ezeti- mibe （study group） were compared to patients treated with statins only （control group）. RESULTS： The study group included 25 patients and the control group 168. All patients in the study were treated with statins. The study group included 13 males （52%） and 12 females （48%）, the control group 76 males （45%） and 92 （55%） females （P = 0.544）. The groups did not differ in age （mean age： 68 ± 8 years, range 53-85 years vs mean age： 71±8 years, range 51-85 years; P = 0.153） or in the rate of dia- betic and hypothyroid patients [11 （44%） vs 57 （33%）, P = 0.347 in the study group and 5 （20%） vs 23 （14%）, P = 0.449 in the control group, respectively]. Patients in the study group were treated with ezetimibe for an average of 798±379 d. Cholelithiasis was found in 4 （16%） patients in the study group and in 33 （20%） patients in the control group （P = 0.666）. CONCLUSION： Ezetimibe does not appear to influ- ence the prevalence of gallstones.
文摘目的研究姜黄素与高脂饮食小鼠胆囊胆固醇性结石关系及可能参与调控过程的因子。方法将C57BL6小鼠50只随机分为5组,其中一组予普通饲料,其余四组予高脂饮食饲料,同时灌喂不同剂量姜黄素[0、200、500、1 000 mg/(kg·d)],共4周。计算小鼠胆囊结石成石率,收集小鼠血液、胆囊胆汁、胆囊、肝脏以及小肠。计算胆囊容积,称量肝脏质量,检测血液及胆汁胆固醇、甘油三酯等生化指标。用Realtime PCR及Western blotting方法分别检测小鼠小肠上皮NPC1L1及SREBP2 m RNA及蛋白表达。结果姜黄素能够降低小鼠胆囊结石的发生,大剂量姜黄素可降低胆囊结石发生率达60%,同时降低肝脏脂肪变性程度,降低小鼠血液胆固醇饱和度。同时,姜黄素可以抑制高脂饮食所致的NPC1L1 m RNA表达上调[(2.65±0.04)vs(2.06±0.07),(1.69±0.06),(1.33±0.05),P<0.01],且呈现剂量依赖关系,降低高脂饮食所致的NPC1L1蛋白高表达。姜黄素还可以抑制高脂饮食所致的SREBP2 m RNA表达上调[(1.34±0.08)vs(1.39±0.03),(1.19±0.01),(1.06±0.03),P<0.05],且呈现剂量依赖关系,降低高脂饮食所致的SREBP2蛋白表达上调。结论姜黄素能够降低高脂饮食小鼠胆囊结石的形成,NPC1L1和SREBP2可能参与了这个过程。
文摘目的:研究尼曼匹克C1样1(Niemann Pick C1 like 1,NPC1L1)基因启动子-762T>C多态性的活性差异及药物对其的调节作用。方法:分别构建含NPC1L1基因-762T>C多态性的T/C等位基因启动子荧光酶报告基因,测定启动子活性以及不同药物处理后启动子活性的改变。结果:含T或C等位基因的NPC1L1基因启动子活性无统计学差异(P>0.05)。外源性胆固醇和依泽麦布均在高浓度抑制两种启动子活性,辛伐他汀则增强两种启动子活性(P<0.05),但两种基因型启动子之间对药物依泽麦布和辛伐他汀的反应无统计学差异(P>0.05)。结论:胆固醇和依泽麦布能抑制NPC1L1转录活性活性,辛伐他汀则增强NPC1L1转录活性,而-762T>C多态性不影响启动子活性及药物反应。
